PET/CT Clinical Trial - PET-DECT for Staging & Imaged Based Radiotherapy

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The overall goal of this project is to investigate the diagnostic performance of integrated F-18 fluorodeoxyglucose-positron emission tomography (FDG-PET) and Dual Energy CT (DECT) imaging in determining the thoracic nodal status of small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), and its impact on target volume delineation for image guided radiation therapy (IGRT) planning.

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT06207747` - Quantitative Analysis of PET/CT Images of Immune Related Side Effects in Metastatic Melanoma Patients	N/A

NCT number	NCT03146117
Study type	Observational
Source	Medical University of South Carolina
Contact
Status	Terminated
Phase
Start date	April 1, 2017
Completion date	June 15, 2018

PET-DECT for Staging and Imaged Based Radiotherapy Planning in Lung Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms